Oncimmune is an early cancer detection company, developing and commercialising products to diagnose cancer in the United Kingdom and North American markets. The company engages in the development of an autoantibody based platform to allow cancer detection for a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT-Liver to aid in the detection and confirmation of hepatocellular carcinoma in high-risk patients with liver lesions of all sizes tests for liver cancer. Oncimmune Holdings Plc was incorporated in 2015 and is headquartered in Nottingham, the United Kingdom.